Pioglitazone - Takeda
Alternative Names: Actos; AD-4833; CT-L03-301; Glustin; PGZ; Piozone; U 72107; U 72107A; U 72107E; ZactosLatest Information Update: 02 Sep 2024
At a glance
- Originator Takeda
- Developer Celltrion; Duke University Medical Center; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd; Novo Nordisk; Piramal Enterprises; Takeda; Takeda Pharmaceuticals USA; Tianjin Takeda; Zinfandel Pharmaceuticals
- Class Antihyperglycaemics; Small molecules; Thiazolidinediones
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase II Non-alcoholic steatohepatitis
- Discontinued Alzheimer's disease; Atherosclerosis; Multiple sclerosis
Most Recent Events
- 26 Aug 2024 Phase-III clinical trials in Type 2 diabetes mellitus (Combination therapy) in South Korea (PO) (NCT06571591)
- 01 Dec 2020 Celltrion completes an agreement to acquire pioglitazone from Takeda Pharmaceuticals
- 11 Jun 2020 Celltrion entered into an agreement to acquire pioglitazone from Takeda Pharmaceuticals